文献速递组学、生物样本库与精准医学基础与转化研究流行病学与生物统计

慢性肺移植物功能障碍发生前的内皮失调多组学生物标志物:一项前瞻性队列研究

Multi-omics biomarkers of endothelial dysregulation preceding chronic lung allograft dysfunction: A prospective cohort study.
PubMed 文献 · PLoS Med · 2026-06-23

该前瞻性队列研究对56例无CLAD的肺移植受者纵向采集BAL进行微生物、代谢、脂质和基因表达多组学分析,并比较13例无CLAD与13例发生CLAD患者的BAL。结果发现CLAD发生前存在鞘脂增加及内皮功能和免疫细胞招募相关基因上调,多组学整合提示这些分子可能作为CLAD早期生物标志物,但研究样本量小且为关联性发现。

要点

  • 肺移植后6个月内BAL微生物多样性下降,葡萄球菌和念珠菌丰度增加,固有和适应性免疫反应上调。
  • CLAD发生前可检测到鞘脂增加及糖萼、免疫细胞招募相关基因上调,提示血管功能障碍和免疫细胞浸润。
  • 多组学整合提示鞘脂分子及内皮功能和免疫细胞招募相关基因是CLAD发生的候选生物标志物。

核心结论

  • 研究识别了与CLAD发生相关的免疫过程、代谢物、脂质和基因,但为关联性发现,不旨在确立因果关系。

研究设计与样本

  • 假设生成性前瞻性队列研究,对56例无CLAD肺移植受者移植后长达30个月的纵向BAL进行微生物、代谢、脂质和基因表达分析,并比较13例无CLAD与13例发生CLAD患者的BAL。

主要发现

  • 无CLAD患者移植后前6个月微生物多样性降低、葡萄球菌和念珠菌丰度增加,固有和适应性免疫反应上调及一氧化氮代谢升高(FDR < 0.05)。
  • 维持免疫抑制减量后,无CLAD患者转为稳态组织修复和T细胞基因(如CD3、GZMA、IL2RB、CD28、CD40LG、LCK)再激活(FDR < 0.05)。
  • 发生CLAD的患者在发病前出现鞘脂丰度增加及糖萼和免疫细胞招募基因(如HAPLN3、HS3ST3B1、SULF2、CHST2、CSGALNACT1、CXCR1、CSF3R、SELL、CXCL2、CEACAM1)上调(FDR < 0.05)。
  • 该基因表达特征在移植后1.5个月持续存在,并在肺功能开始下降时强度增加;单细胞数据集比对显示该特征表达于单核细胞、内皮细胞和T细胞。

临床怎么用

  • 多组学候选生物标志物(鞘脂分子及内皮功能、免疫细胞招募相关基因)可能有助于在肺功能下降前识别CLAD高风险患者。
  • 研究结果尚需在独立验证队列中使用定量PCR和靶向质谱等方法确认,暂不能直接用于临床决策。

局限性

  • 研究样本量小。
  • 研究结果为关联性,不旨在确立因果关系。
  • 需要在独立验证队列中使用靶向方法确认发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term survival of lung transplant recipients remains limited by chronic lung allograft dysfunction (CLAD). CLAD is only diagnosed following a persistent and substantial decline in lung function, after which irreversible damage to the lungs has occurred, limiting opportunities to effectively intervene at an early stage. There is a critical need for earlier detection prior to its clinical manifestation. The immunological drivers of CLAD remain unclear, limiting the development of predictive biomarkers and new therapies. METHODS AND FINDINGS: In this hypothesis-generating, prospective cohort study, we profiled the microbial, metabolic, lipidomic, and gene expression dynamics of longitudinally collected broncho-alveolar lavages (BALs) from 56 CLAD-free lung transplant recipients up to 30 months post-transplant, and compared BALs from 13 CLAD-free patients to BALs from 13 patients who developed CLAD. In CLAD-free patients, the first 6 months post-transplant were hallmarked by diminished microbial diversity and increased abundance of Staphylococcus and Candida, coupled with upregulated innate and adaptive immune responses, and elevated nitric oxide metabolism (FDR < 0.05). This was superseded by homeostatic tissue repair and by the reactivation of T-cell genes such as CD3, GZMA, IL2RB, CD28, CD40LG, and LCK, after tapering of maintenance immunosuppression (FDR < 0.05). In patients who developed CLAD, disease onset was preceded by the increased abundance of sphingolipids and the upregulation of glycocalyx and immune cell recruitment genes such as HAPLN3, HS3ST3B1, SULF2, CHST2, CSGALNACT1, CXCR1, CSF3R, SELL, CXCL2, and CEACAM1 (FDR < 0.05), suggesting increased vascular dysfunction and immune cell graft infiltration prior to CLAD onset. Scoring against a publicly available lung single-cell dataset showed our bulk gene transcriptomics signature to be expressed by monocytes, endothelial, and T cells. In contrast to CLAD-free patients, this signature persisted after 1.5 months post-transplant and increased in intensity upon the start of lung function decline. Multi-omics integration highlighted sphingolipid molecules and genes involved in immune cell recruitment and endothelial function as candidate biomarkers associated with the onset of CLAD. This study is limited by its small sample size. CONCLUSIONS: We have identified immunological processes, metabolites, lipids, and genes associated with the onset of CLAD. Our findings are to be considered associative and not aimed at establishing causality. Future studies employing a targeted approach in independent validation cohorts, using, for example, quantitative polymerase chain reaction (PCR) and targeted mass-spectrometry, will be required to confirm these findings.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Iacono G, Begka C, Cardwell B, et al. Multi-omics biomarkers of endothelial dysregulation preceding chronic lung allograft dysfunction: A prospective cohort study. PLoS Med. 2026. PMID: 42335172. doi:10.1371/journal.pmed.1004725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。